Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Procizumab in healthy male volunteers
NCT06331884Phase 1Completed
- Sponsor
- 4TEEN4 Pharmaceuticals
- Start
- Mar 2024
- Primary completion
- Aug 2024
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of invobenitug in cardiogenic shock and septic shock (4 arms), sponsored by 4TEEN4 Pharmaceuticals. Primary endpoint: Safety and Tolerability at 28 days. Started Mar 2024; status: completed.
02
Drugs
invobenitug
03
Conditions
cardiogenic shockseptic shock
Beyond the preview
Go deeper on NCT06331884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06331884.